% Expired Patents = 45.5

CIPO Patents = 1

EPO Patents = 4

Forward Citations = 41

Loading Chart...

3 inventors (with patents filed for the assignee):

Andrew Vaillant (11 out of 13 patents)

Michel Bazinet (6 out of 8 patents)

Jean-Marc Juteau (4 out of 4 patents)

11 patents: Sort by Forward Citations

1. 9616083 - Oligonucleotide chelate complex methods (2017-04-11),

2. 9603865 - Methods for the treatment of hepatitis B and hepatitis D virus infections (2017-03-28),

3. 9533003 - Methods for the treatment of hepatitis B and hepatitis D infections (2017-01-03),

4. 9492506 - Oligonucleotide chelate complex—polypeptide compositions and methods (2016-11-15),

5. 9133458 - Methods for the treatment of hepatitis B and hepatitis D infections (2015-09-15),

6. 8716259 - Oligonucleotide chelate complexes (2014-05-06),

7. 8513211 - Oligonucleotide chelate complexes (2013-08-20),

8. 8067385 - Antiviral oligonucleotides targeting HBV (2011-11-29),

9. 8008270 - Antiviral oligonucleotides targeting viral families (2011-08-30),

10. 8008269 - Antiviral oligonucleotides (2011-08-30),

11. 7358068 - Antiviral oligonucleotides (2008-04-15),

Replicor Inc is a biopharmaceutical company dedicated to the discovery and development of antiviral therapeutics for chronic HBV and HBV/HDV co-infection. Replicor's mission is to improve the lives of patients suffering from these infections through innovative research and drug development.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

11 Patents

#98 in Montreal

#1,377 in Canada

#51,671 in the World

Montreal, Canada

Replicor Inc

Forward Citations = 41

3 inventors:

Andrew Vaillant (11 out of 13 patents)

Michel Bazinet (6 out of 8 patents)

Jean-Marc Juteau (4 out of 4 patents)

Please report any incorrect information to [email protected]

1 patent (CIPO):

Please report any incorrect information to [email protected]

4 patents (EPO):

Please report any incorrect information to [email protected]